COMPARISON OF CONTINUOUS-INFUSION AND BOLUS ADMINISTRATION OF IFOSFAMIDE IN CHILDREN

被引:37
作者
BODDY, AV
YULE, SM
WYLLIE, R
PRICE, L
PEARSON, ADJ
IDLE, JR
机构
[1] UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT CHILD HLTH,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND
[2] UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT PHARMACOL SCI,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND
关键词
IFOSFAMIDE; PHARMACOKINETICS; METABOLISM; BOLUS; INFUSION;
D O I
10.1016/0959-8049(95)00090-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The pharmacological effects of ifosfamide (IFO) are dependent on its metabolism which may vary between different modes of administration. This was studied in 17 patients who received both a continuous infusion (9 g/m(2) over 72 h) and repeated bolus administration (3 g/m(2) every 24 h for 3 days). Concentrations of IFO and its metabolites were determined in plasma and urine. There was up to 70% less of the dechloroethylated metabolites in plasma following bolus administration compared to continuous infusion. Since dechloroethylation results in the formation of the toxic metabolite chloroacetaldehyde, this difference in metabolism may have an impact on the toxicity of IFO. There were no other consistent differences between the two modes of administration. Autoinduction of IFO metabolism, with an increase in dechloroethylated metabolites, was observed for both modes of administration. In conclusion, apart from dechloroethylation, there is little difference between these two modes of administration. However, during multiple cycles of IFO therapy such differences could have a significant effect.
引用
收藏
页码:785 / 790
页数:6
相关论文
共 25 条
[1]  
ALLEN LM, 1976, CANCER TREAT REP, V60, P451
[2]   A RANDOMIZED STUDY OF INTRAVENOUS BOLUS VERSUS CONTINUOUS INFUSION OF IFOSFAMIDE AND DOXORUBICIN WITH ORAL ETOPOSIDE FOR SMALL-CELL LUNG-CANCER [J].
ANDERSON, H ;
PRENDIVILLE, J ;
THATCHER, N ;
RADFORD, JA ;
SWINDELL, R .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1991, 117 :S139-S140
[3]   RESPONSE TO IFOSFAMIDE AND MESNA - 124 PREVIOUSLY TREATED PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA [J].
ANTMAN, KH ;
RYAN, L ;
ELIAS, A ;
SHERMAN, D ;
GRIER, HE .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (01) :126-131
[4]  
Boddy A. V., 1992, Pharmaceutical Research (New York), V9, pS314
[5]  
Boddy A. V ., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P246
[6]   COMBINED THIN-LAYER CHROMATOGRAPHY PHOTOGRAPHY DENSITOMETRY FOR THE QUANTIFICATION OF IFOSFAMIDE AND ITS PRINCIPAL METABOLITES IN URINE, CEREBROSPINAL-FLUID AND PLASMA [J].
BODDY, AV ;
IDLE, JR .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1992, 575 (01) :137-142
[7]  
BODDY AV, 1995, CANCER CHEMOTH PHARM, V36, P53
[8]  
BODDY AV, 1993, CANCER RES, V53, P3758
[9]   DOSING AND SIDE-EFFECTS OF IFOSFAMIDE PLUS MESNA [J].
BRADE, WP ;
HERDRICH, K ;
KACHELFISCHER, U ;
ARAUJO, CE .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1991, 117 :S164-S186
[10]   SUBCUTANEOUS CONTINUOUS INFUSION OF IFOSFAMIDE AND CYCLOPHOSPHAMIDE IN AMBULATORY CANCER-PATIENTS - BIOAVAILABILITY AND FEASIBILITY [J].
CERNY, T ;
GRAF, A ;
ROHNER, P ;
ZEUGIN, T ;
BRUNNER, KW ;
KUPFER, A .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1991, 117 :S129-S134